ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00496184
Recruitment Status : Completed
First Posted : July 4, 2007
Last Update Posted : May 8, 2008
Sponsor:
Information provided by:
Western Galilee Hospital-Nahariya

Brief Summary:
To evaluate the use of topical application of Nifedipine cream for the treatment of Provoked localized Vulvodynia (vestibulitis, vestibulodynia).

Condition or disease Intervention/treatment Phase
Vulvar Diseases Vulvar Pain Vestibulitis Vestibulodynia Vulvodynia Drug: Nifedipine cream topical application Phase 3

Detailed Description:

30 women aged 18-45 diagnosed with Provoked localized Vulvodynia will be included. 10 women will use topical Nifedipine cream 0.2% 4 times a day for 6 weeks (except for menstrual period). 10 other women will use topical Nifedipine cream 0.4% 4 times a day for 6 weeks (except for menstrual period).

10 women will be a control group and will use a placebo cream. The study will be randomized and double blind. Participants will be examined before starting the treatment, at the end of the treatment and 3 months after completion the treatment. A special detailed questionnaire has been prepared in three languages and will be used to compare dyspareunia and associate variables between the groups.

The Q-tip tests will be performed and findings will be drawn in each examination. Differences between the groups will be examined, and uni- and multi-variate analysis will be performed.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Topical Application of Nifedipine Cream for the Treatment of Vulvar Vestibulitis Syndrome
Study Start Date : April 2006
Actual Primary Completion Date : October 2007
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Nifedipine




Primary Outcome Measures :
  1. Complete resolution of vestibulitis. [ Time Frame: Participants will be examined before starting the treatment, at the end of the treatment and 3 months after completion the treatment, using the questionnaire and the Q-tip applicator for detection of vestibular sensitivity. ]

Secondary Outcome Measures :
  1. Safety of the Nifedipine treatment. [ Time Frame: Participants will be examined before starting the treatment, at the end of the treatment and 3 months after completion the treatment, using the questionnaire. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women diagnosed with vestibulitis according to Friedrich's criteria:

    • Severe pain with vestibular touch or attempted vaginal entry.
    • A positive Q-tip test: pain produced by touching the vestibule with a cotton tipped applicator.
    • Physical findings limited to varying degree of vestibular erythema.
  2. Non-pregnant women aged 18-45.
  3. Women use effective contraception and are not interested in becoming pregnant during the study period.
  4. No known Nifedipine allergy.
  5. No medical diseases.

Exclusion Criteria:

  1. Women who have undergone vestibulectomy.
  2. Active vaginal or pelvic infection.
  3. A medical disease uch as Diabetes, immune suppression.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00496184


Locations
Israel
Colposcopy Clinic, Obstetrics and Gynecology Department, Western galilee Hospital
Nahariya, Israel
Department of Obstetrics and Gynecology
Nahariya, Israel
Sponsors and Collaborators
Western Galilee Hospital-Nahariya
Investigators
Principal Investigator: Jacob Bornstein, MD Western Galilee Hospital, Nahariya, Israel
Principal Investigator: Doron Zarfati, MD Western Galilee Hospital, Nahariya, Israel

Publications:
ClinicalTrials.gov Identifier: NCT00496184     History of Changes
Other Study ID Numbers: 20050989
First Posted: July 4, 2007    Key Record Dates
Last Update Posted: May 8, 2008
Last Verified: May 2008

Keywords provided by Western Galilee Hospital-Nahariya:
Nifedipine treatment
Vestibulitis
Placebo

Additional relevant MeSH terms:
Vulvodynia
Vulvar Vestibulitis
Vulvar Diseases
Genital Diseases, Female
Vulvitis
Nifedipine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs